am.lundgren
Submits third-party assay reports on material purchased directly. Based in Aarhus.
Section 1
Contribution
Purchases material, pays for assays, and submits the resulting reports to the index.
Records submitted
9
n=9
Annotations
0
n=0
Median purity submitted
98.71%
n=9
Suppliers covered
7
n=9
Section 2
Records submitted
A submitter chose to buy this material and to pay for this assay. That choice is the selection mechanism behind the whole index and it is not random.
| Report | Compound | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042607 | Semaglutide | SWB | SWB-2602-X6980 | Janoshik | 2026-Q3 | 98.74 | 4.52 | 94.7 | Buyer-sourced | 0 | PASS |
| AX-2026-043159 | Semaglutide | KP | KP-2601-K5731 | Janoshik | 2026-Q2 | 97.80 | 5.52 | 105.4 | Buyer-sourced | 0 | PASS |
| AX-2026-043329 | Tirzepatide | GL Biochem | GLBI-2510-N8702 | VendorInvestigate | 2026-Q1 | 97.39 | 3.06 | 107.5 | Buyer-sourced | 2 | MARGINAL |
| AX-2025-019593 | Semaglutide | Homopeptide | HOMO-2511-G2269 | Nordanalyt | 2025-Q4 | 99.93 | 6.63 | — | Buyer-sourced | 0 | PASS |
| AX-2025-020047 | MK-677 (Ibutamoren mesylate) | SWB | SWB-2505-G7429 | Janoshik | 2025-Q3 | 99.84 | 3.72 | 90.3 | Buyer-sourced | 0 | FAIL |
| AX-2025-018886 | BPC-157 | FGP | FGP-2409-Y9965 | Medutest | 2025-Q1 | 99.93 | 4.56 | 103.9 | Buyer-sourced | 0 | PASS |
| AX-2024-005202 | IGF-1 LR3 | KP | KP-2406-K5818 | PeptideMeter | 2024-Q3 | 98.39 | 6.06 | 105.0 | Buyer-sourced | 0 | PASS |
| AX-2024-004731 | Tirzepatide | TFC | TFC-2405-W8094 | Janoshik | 2024-Q2 | 98.71 | 5.80 | — | Supplier-supplied | 0 | PASS |
| AX-2024-005005 | Tirzepatide | ERP | ERP-2401-D7665 | Medutest | 2024-Q2 | 98.26 | 4.79 | — | Buyer-sourced | 0 | PASS |
| Supplier | Records | Median purity |
|---|---|---|
| SWB | 2 | n<3 |
| KP | 2 | n<3 |
| GL Biochem | 1 | n<3 |
| Homopeptide | 1 | n<3 |
| FGP | 1 | n<3 |
| TFC | 1 | n<3 |
| ERP | 1 | n<3 |